BASF relocates Kolliphor TPGS production from US to Germany

BASF headquarters in Germany.

LUDWIGSHAFEN, GERMANY: BASF will transfer the pharmaceutical production of Kolliphor TPGS manufactured at the company’s Kankakee site, Illinois, US, to Minden facility, Germany. The transition is expected to be completed by the first quarter of 2014. Until the production in Minden is fully operational, BASF will continue to manufacture Kolliphor TPGS at the Kankakee site, which will fully support pharmaceutical and nutraceutical customers during the transition.

“Expanding the Kolliphor TPGS manufacturing capacity at our Minden site is another example of BASF’s commitment to the pharmaceutical and dietary supplement market. The relocation creates a more centralized production facility, reduces complexity in the production setup, and provides room for future expansion,” said Dr Thorsten Schmeller, Head of Global Marketing New Products, Global Business Unit Pharma Ingredients & Services, BASF.

© WOC News